Antengene

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

Antengene Selected as a Constituent of the FTSE Global Equity Index Series

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Included in the Shenzhen-Hong Kong Stock Connect

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Index-es Including the Hang Seng Composite Index